Skip to main content
. Author manuscript; available in PMC: 2019 Nov 27.
Published in final edited form as: Environ Mol Mutagen. 2019 Feb 27;60(6):513–533. doi: 10.1002/em.22274

Fig. 6.

Fig. 6.

Left panel: BMD analyses of aneugen compounds represented in cross system plots with BMD50 CIs for in vitro MN against BMD50 CIs 24 hr p-H3 responses in TK6 cells, with both x and y axes representing Log10 concentration of compounds in μM. The dashed parallel lines are drawn in such a way that encompasses most of the CIs. Dashed square box represents default PROAST output encompassing finite BMD CIs. Compound “car” falls outside the trend with unbound CI in the 24 hr p-H3 endpoint. Right panel: BMD50 CIs for in vitro MN against BMD50 24 hr p53 responses in TK6 cells, with both x and y axes representing Log10 concentration of compounds in μM. Dashed parallel lines encompass most of the BMD CIs, similarly to the left panel correlation plot. Dashed square box represents default PROAST output encompassing finite BMD CIs. Compounds “gli” and “des” lie outside the general observed trend, with unbound upper CI in the 24 hr p53 endpoint. Dashed horizontal lines obtain the uncertainty range with corresponding circles intercept with the x axis predicting the BMD50 for in vitro MN response. See Table I for compound abbreviations (BMD, Benchmark Dose; CI, confidence interval; MN, micronucleus).